13q Deletion in CLL: Impact on Prognosis and Treatment

Deletion of part of the long arm of chromosome 13, specifically at band 13q14, is the single most common genetic abnormality in chronic lymphocytic leukemia and, when it appears as the only chromosomal change, it signals a relatively favorable outlook. Patients in this group have a median survival measured in years longer than those with other well-known CLL-associated deletions. Yet the picture is more complicated than “good prognosis” suggests, because the size of the deletion, the fraction of leukemia cells carrying it, and what other genetic changes tag along all shift the clinical picture in ways that matter for treatment decisions.

What the 13q14 Deletion Actually Removes

The critical stretch of DNA lost in 13q14 deletions is surprisingly small. The minimal deleted region sits within a roughly 30-kilobase zone that harbors two tiny but powerful genes: miR-15a and miR-16-1. These are microRNAs, short RNA molecules whose job is to dial down the production of certain proteins. In healthy B cells, miR-15a and miR-16-1 keep a tight leash on BCL2, a protein that prevents cells from undergoing their normal programmed death. When the deletion knocks out these microRNAs, BCL2 levels climb, and the leukemia cells become stubbornly resistant to dying on schedule.¹

Both microRNAs sit inside an intronic region of a gene called DLEU2, which itself encodes a long non-coding RNA. DLEU2 is required for miR-15a/miR-16-1 production, so losing this locus is essentially a two-for-one hit against the cell’s anti-cancer defenses.² Studies have shown that the relationship between miR-15a/miR-16-1 and BCL2 is inverse: as microRNA levels fall, BCL2 rises, and BCL2 overexpression is a hallmark of CLL.³ The clinical importance of this connection has only grown since the arrival of venetoclax, a drug that directly blocks BCL2, essentially compensating for what the deletion set in motion.

How 13q Deletion Compares to Other CLL Abnormalities

The landmark study that defined CLL’s cytogenetic risk hierarchy identified five prognostic tiers based on the chromosomal abnormality present. Patients with a 17p deletion had the worst outlook, with a median survival of about 32 months. An 11q deletion came next at roughly 79 months. Trisomy 12 and a normal karyotype occupied the middle ground at around 114 and 111 months, respectively. Patients whose only abnormality was a 13q deletion fared best, with a median survival of about 133 months.⁴ That hierarchy, often called the Döhner classification, remains a backbone of CLL risk stratification to this day.

A large validation of this framework by the CLL Research Consortium confirmed that isolated 13q deletion remains the most favorable prognostic group, with a median time to first treatment of 72 months and overall survival exceeding 12 years from the time the deletion is detected.⁵ These numbers help explain why many patients with isolated 13q deletion are initially managed with watchful waiting rather than immediate treatment. The leukemia can smolder for years without causing symptoms that require intervention.

That said, the favorable label applies specifically to 13q deletion as the sole abnormality. When it shows up alongside a 17p or 11q deletion, the prognosis is driven by the higher-risk partner, not by the 13q deletion. The presence of 13q does not neutralize or soften the impact of those more aggressive changes.

Not All 13q Deletions Are Created Equal

Lumping every patient with an isolated 13q deletion into one “good prognosis” bucket turns out to miss a lot. Researchers have identified at least three features of the deletion itself that influence how the disease behaves: the physical size of the deleted region, the fraction of leukemia cells that carry it, and whether the deletion hits one or both copies of chromosome 13.

Deletion Size Matters

The minimal deleted region that takes out miR-15a/miR-16-1 is relatively small and is sometimes called a type I or class I deletion. Some patients have much larger deletions that extend further along 13q and swallow additional genes, including the retinoblastoma gene RB1. These bigger deletions, referred to as type II or class II, carry a measurably worse outlook. One study found that patients with the larger class II deletion had a significantly increased risk of disease progression, with an odds ratio over twelve times higher than those with the smaller deletion, independent of other prognostic markers.⁶ Separate work confirmed that overall survival was significantly shorter for patients with type II lesions compared to type I.⁷

This distinction has practical consequences. A patient whose FISH report says “13q deletion” without specifying whether RB1 is involved is getting an incomplete picture. If the deletion extends into RB1 territory, the “favorable” label may overstate things. Not all labs routinely report the size of the deletion, so patients and their physicians may want to clarify this with the pathology team.

The Percentage of Deleted Cells

Another source of variability is how many leukemia cells in the sample actually carry the deletion. A patient in whom only a small fraction of CLL cells have lost 13q14 behaves differently from one in whom the vast majority of cells are affected. Research has consistently shown that a higher percentage of deleted cells correlates with a shorter time to first treatment. One study found that CLL cases with fewer than 70% of cells carrying the 13q deletion, and without RB1 involvement, had a particularly long time to treatment, while cases with 70% or more deleted cells experienced a significantly shorter interval.⁸

A study in Chinese CLL patients echoed this finding with a different threshold: those with 80% or more deleted cells had a median time to first treatment of just 11 months, compared to 92 months for those below 80%.⁹ The precise cutoff varies across studies, but the direction is consistent: the more the leukemia population is dominated by 13q-deleted cells, the sooner treatment tends to become necessary.

Monoallelic Versus Biallelic Deletion

Humans carry two copies of chromosome 13. A monoallelic deletion means only one copy has lost the 13q14 region; a biallelic deletion means both copies are affected. Early on, there was concern that losing both copies might strip away any residual tumor-suppressor activity and worsen the prognosis. The evidence, however, has not consistently supported that worry.

An analysis of 627 patients with isolated 13q deletions found that the most common pattern was monoallelic loss, making up about 82% of cases, while purely biallelic deletion accounted for roughly 9% and a mixed pattern about 9%. Despite these differences in deletion load, no significant difference in clinical outcome emerged across the three groups.¹⁰ A separate study similarly reported no meaningful difference in time to treatment between monoallelic and biallelic cases.¹¹

Interestingly, data from the CLL8 trial suggested that biallelic deletion might even be associated with a slightly better response to chemoimmunotherapy. Patients with biallelic 13q deletion treated with FCR (fludarabine, cyclophosphamide, and rituximab) had a higher complete response rate than those with monoallelic deletion, and not a single death was observed in the biallelic group treated with FCR during the study period. Among biallelic cases, the mutation status of the immunoglobulin heavy-chain gene did not influence progression-free or overall survival, whereas it remained an important prognostic factor in monoallelic cases.¹² These findings are provocative but come from a single trial context, so the bottom line is that biallelic 13q deletion does not appear to worsen prognosis and may even enhance sensitivity to certain regimens.

How 13q Deletion Is Detected

The standard method for spotting 13q deletion is fluorescence in situ hybridization, or FISH. A lab applies fluorescently labeled probes to the patient’s leukemia cells; each probe binds to a specific chromosomal region. If a signal is missing, that region is deleted. FISH panels for CLL typically test for four abnormalities at once: 13q deletion, 11q deletion, 17p deletion, and trisomy 12. The technique is reliable and well established, but it only looks where its probes are aimed, so it can miss abnormalities outside the targeted regions.

Array-based comparative genomic hybridization offers a broader view, scanning the entire genome for gains and losses. In comparative studies, array CGH detected genetic abnormalities in about 82% of CLL cases compared to 60% for FISH, and identified changes that FISH missed in roughly 16% of cases.¹³ The tradeoff is that array CGH can struggle to detect small clones. One study found that when the abnormal clone made up fewer than 30% of the sample, FISH caught what the array missed.¹⁴ In practice, most CLL centers still rely on FISH as the frontline test, sometimes supplementing with array or sequencing technologies when the clinical picture warrants deeper investigation.

Treatment Response in 13q-Deleted CLL

For patients with isolated 13q deletion who eventually need treatment, the responses to standard chemoimmunotherapy have historically been strong. In a cohort treated with FCR, about 62% achieved a complete response, and the median progression-free survival reached roughly 83 months, or close to seven years. Overall survival at five years was about 90%, and at ten years about 79%.¹⁵ These numbers are among the best across any CLL cytogenetic subgroup and help explain why FCR was long considered the gold standard for fit patients with favorable-risk disease.

The treatment landscape has shifted substantially with targeted therapies. BTK inhibitors and BCL2 inhibitors now dominate frontline and relapse settings. Real-world data on acalabrutinib, a second-generation BTK inhibitor, show that about 40% of tested patients had a 13q deletion at baseline, and the overall progression-free survival rate at 36 months was roughly 83% for the full cohort on first-line treatment.¹⁶ Venetoclax, which directly blocks the BCL2 protein that 13q deletion unleashes, pairs logically with this biology. In the CLL14 trial, venetoclax combined with obinutuzumab achieved undetectable minimal residual disease in about three-quarters of treated patients two months after finishing therapy, vastly outperforming chlorambucil-based treatment.¹⁷

Because the 13q deletion’s primary downstream effect is BCL2 overexpression, venetoclax-based therapy has a compelling biological rationale for this patient group specifically. The drug targets the very protein that the genetic defect deregulates. Whether this translates into superior outcomes for 13q-deleted patients compared to other subgroups remains an area of active study, but the mechanistic fit is hard to ignore.

Clonal Evolution Over Time

A diagnosis of isolated 13q deletion does not guarantee that the leukemia will stay genetically simple. CLL is a disease that evolves. Over time, additional chromosomal abnormalities can appear in subclones that were either undetectable at diagnosis or genuinely absent. In one longitudinal study, about 17% of patients showed clonal evolution within a median follow-up of roughly three and a half years. The newly acquired changes included 17p deletions, 11q deletions, and other high-risk aberrations. Three patients who started with monoallelic 13q deletion later acquired a second 13q deletion on the other chromosome, converting to biallelic status.¹⁸

The acquisition of a 17p deletion is the most clinically consequential form of clonal evolution, because it signals resistance to conventional chemotherapy and a sharply worse prognosis. In the same study, patients who gained a 17p deletion saw the proportion of cells carrying it grow over time, consistent with a survival advantage for that subclone. This underscores why repeat cytogenetic testing before starting each new line of therapy is recommended in many guidelines: the risk profile at relapse may look nothing like the one at diagnosis.

The Immune Microenvironment Connection

Recent research has added another dimension to the 13q deletion story that goes beyond the leukemia cells themselves. The DLEU2/miR-15a/miR-16-1 cluster appears to influence the immune cells surrounding the tumor. A 2024 mouse model that combined CLL-driving TCL1 overexpression with germline deletion of the minimal deleted region found that losing this cluster pushed monocyte differentiation and macrophage polarization toward a tumor-supportive state. T cells in these mice were also dysfunctional. The deletion correlated inversely with levels of BCL2 and PD-1/PD-L1 on both leukemia cells and immune cells.¹⁹

If the deletion does shape the immune microenvironment in human CLL as well, it could have implications for immunotherapy approaches. PD-1/PD-L1 checkpoint inhibitors, bispecific T-cell engagers, and CAR-T therapies all depend on a functional or at least recoverable immune system. Understanding how the most common CLL genetic change alters the tumor’s immune neighborhood is still early-stage work, but it could eventually help explain why some 13q-deleted patients respond differently to immune-based treatments than their overall favorable prognosis might predict.

Co-occurring Mutations and Integrated Risk

Modern genomic profiling goes well beyond FISH. Next-generation sequencing panels now routinely check for point mutations in genes like TP53, NOTCH1, SF3B1, and ATM, alongside the classical cytogenetic abnormalities. In the CLL14 trial population, del(13q) was present in about 35% of patients using the traditional hierarchical model, while NOTCH1 mutations appeared in roughly 23%, SF3B1 mutations in 16%, ATM mutations in 13%, and TP53 mutations in 10%.²⁰

A 13q deletion sitting alongside a NOTCH1 or SF3B1 mutation is not the same disease as an isolated 13q deletion with no co-mutations. Integrated prognostic models now fold in IGHV mutation status, gene mutations, and serum markers alongside the FISH result to create a more granular risk picture. For patients, this means that the isolated FISH finding of 13q deletion is an important starting point but rarely the whole story. The more complete the genetic workup, the more accurately the disease can be characterized and monitored over time.